Loading
ThyGeNEXT is a genetic test from Interpace Biosciences, run on a thyroid nodule sample, that looks for the mutations most often found in thyroid cancer.
ThyGeNEXT is Interpace Biosciences' oncogene and mRNA fusion panel for indeterminate thyroid nodules, those cytology cannot call benign or malignant. Interpace states the markers inform diagnosis, prognosis and treatment aligned to FDA-approved therapies for RET, NTRK and other alterations. Its result is combined with ThyraMIR v2 to refine the malignancy risk.
A next-generation DNA and RNA sequencing panel of the commonest thyroid cancer mutations and mRNA fusions, including RET and NTRK, whose result is combined with the ThyraMIR v2 microRNA test, as described by Interpace Biosciences.
1.ThyGeNEXT binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ThyGeNEXT" OR ABSTRACT:"ThyGeNEXT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ThyGeNEXT, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/